Oncology · Clinical trials
Non-Small-Cell Lung Cancer Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About non-small-cell lung cancer — and why its trials are hard
Non-small-cell lung cancer (NSCLC) accounts for roughly 85% of lung cancers and has become the flagship example of precision oncology. Treatment now hinges on comprehensive molecular profiling and PD-L1 testing at diagnosis. For tumors with targetable driver mutations, oral targeted therapies deliver deep, durable responses: osimertinib is standard for EGFR-mutant disease (FLAURA), alectinib for ALK rearrangements (ALEX), and agents like sotorasib and adagrasib address the previously undruggable KRAS G12C mutation, while amivantamab targets EGFR exon 20 insertions. For tumors without actionable drivers, immune checkpoint inhibitors reshaped care: pembrolizumab monotherapy for high PD-L1 tumors (KEYNOTE-024) and pembrolizumab plus chemotherapy regardless of histology (KEYNOTE-189 for nonsquamous, KEYNOTE-407 for squamous) are first-line standards. Immunotherapy has also moved into earlier stages as adjuvant, neoadjuvant, and perioperative therapy. These advances have meaningfully extended survival, with subsets of driver-positive and immunotherapy-responsive patients achieving multi-year disease control that was unimaginable in the cytotoxic-only era.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Osimertinib (Tagrisso) | 2018 (first-line) | First-line EGFR exon 19 del/L858R-mutant advanced NSCLC | FLAURA (Phase III) | PFS then overall survival vs first-gen EGFR-TKI | Median PFS 18.9 vs 10.2 months; median OS 38.6 vs 31.8 months (OS HR 0.80) |
| Pembrolizumab (monotherapy) (Keytruda) | 2016 | First-line PD-L1 >=50%, no EGFR/ALK alteration | KEYNOTE-024 (Phase III) | PFS and overall survival vs chemotherapy | Median OS 30.0 vs 14.2 months in long-term follow-up; PFS HR 0.50 |
| Pembrolizumab + chemotherapy (Keytruda) | 2017-2018 | First-line metastatic nonsquamous (KEYNOTE-189) and squamous (KEYNOTE-407) | KEYNOTE-189 (Phase III) | Overall survival vs chemotherapy alone | OS HR ~0.49 (nonsquamous); benefit across PD-L1 levels |
| Alectinib (Alecensa) | 2017 | First-line ALK-positive advanced NSCLC | ALEX (Phase III) | Progression-free survival vs crizotinib | PFS HR 0.47; median PFS ~34.8 vs 10.9 months, with strong CNS control |
| Sotorasib (Lumakras) | 2021 | Previously treated KRAS G12C-mutant advanced NSCLC (accelerated approval) | CodeBreaK 100 (Phase II) | Objective response rate | ORR ~36%; first approved KRAS G12C inhibitor |
| Amivantamab (Rybrevant) | 2021 | EGFR exon 20 insertion-mutant NSCLC after platinum (accelerated approval) | CHRYSALIS (Phase I) | Objective response rate | ORR ~40%; first approved therapy for EGFR exon 20 insertions |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in non-small-cell lung cancer development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Durvalumab +/- tremelimumab — MYSTIC (Phase III) | Failed to meet primary endpoints in first-line metastatic NSCLC | Durvalumab did not significantly improve OS over chemotherapy in PD-L1 >=25% patients, and the durvalumab-tremelimumab combination missed its OS and PFS endpoints |
| Pembrolizumab + ipilimumab — KEYNOTE-598 (Phase III) | Failed; no benefit over pembrolizumab alone | Adding ipilimumab to pembrolizumab in PD-L1 >=50% NSCLC did not improve OS or PFS and increased toxicity, so the trial was stopped for futility |
| Sotorasib (second-line, confirmatory) — CodeBreaK 200 (Phase III) | Only modest PFS benefit vs docetaxel; no OS improvement | Met PFS but the magnitude was limited and OS was not significantly improved, tempering enthusiasm for first-generation KRAS G12C inhibitors |
Choosing the right endpoint
Primary endpoints that matter in non-small-cell lung cancer trials
- Overall survival (OS) — The definitive endpoint; immunotherapy regimens (KEYNOTE-024/189) and osimertinib demonstrated clear OS gains.
- Progression-free survival (PFS) — The workhorse endpoint for targeted therapies, where deep responses produce dramatic PFS separation (e.g., ALEX, FLAURA).
- Objective response rate (ORR) — Basis for accelerated approvals of driver-targeted agents (sotorasib, amivantamab) in biomarker-selected populations.
- CNS/intracranial activity — A key differentiator for TKIs given the high brain-metastasis rate; osimertinib and alectinib show strong CNS penetration.
- PD-L1 expression / biomarker selection — PD-L1 tumor proportion score and driver-mutation status determine first-line eligibility and regimen choice.
How iNGENū runs non-small-cell lung cancer trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Non-Small-Cell Lung Cancer clinical trials — FAQs
How is first-line treatment chosen in advanced NSCLC?
What changed with KRAS-targeted drugs?
Why have some immunotherapy combinations failed?
Ready to discuss your non-small-cell lung cancer trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal